Pro Medicus Ltd (ASX: PME) shares have come under pressure this year.
While this is disappointing for shareholders, it could be an opportunity for others to snap up the health imaging technology company's shares.
That's the view of two analysts, who are urging investors to buy Pro Medicus shares this week, according to The Bull.
Image source: Getty Images
What are they saying about Pro Medicus shares?
The team at Catapult Wealth has named Pro Medicus as a buy this week. It highlights that the company has a positive long-term growth outlook thanks partly to its growing market share in the massive United States market.
It also notes that a couple of key contract renewals have demonstrated strengthening pricing power despite artificial intelligence (AI) disruption concerns. It explains:
Pro Medicus develops advanced medical imaging software used by major hospitals and radiology groups globally. The company reported a strong first half result in fiscal year 2026, with revenue up 28.4 per cent to $124.8 million and underlying profit before tax rising 29.7 per cent to $90.7 million. In March, PME secured two important contract renewals worth a minimum of $40 million, both at higher transaction fees, signalling strengthening pricing power.
With an underlying earnings before interest and tax margin at 73 per cent and cash of $222 million, PME remains financially robust. Growing US market share supports a positive long term growth outlook, making PME an attractive portfolio addition.
Who else is bullish?
Also tipping Pro Medicus shares as a buy this week is MPC Markets.
It believes that recent share price weakness has created an attractive entry point for investors, especially given its position as one of the highest quality software companies on the Australian share market. It said:
The company provides medical imaging software and services to hospitals and healthcare groups across the world. Its software has quietly become the dominant choice across some of the largest hospital networks in the United States. The product is faster, more scalable and modern than what its competitors offer. Artificial intelligence is built in, so it complements the business.
The share price plunge has been driven by broad technology sentiment as opposed to issues with the business. Earnings are still growing and the company still wins major new hospital contracts. In our view, the market has handed investors an appealing entry point into one of the best software businesses on the ASX. We retain our buy recommendation.
